StonvexLoading…
StonvexCore line items from TME's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 | Annual 2021 2021-12-31 |
|---|---|---|---|---|
Revenue | ¥28.40B | ¥27.75B | ¥28.34B | ¥31.24B |
Operating Income | ¥8.71B | ¥6.06B | ¥4.44B | ¥3.80B |
Net Income | ¥7.11B | ¥5.22B | ¥3.84B | ¥3.21B |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | ¥90.44B | ¥75.54B | ¥67.01B | ¥67.25B |
Total Liabilities | ¥20.72B | ¥18.33B | ¥17.88B | ¥16.20B |
Cash & Equivalents | ¥13.16B | ¥13.57B | ¥9.55B | ¥6.59B |
Free Cash Flow OCF − CapEx | ¥9.96B | ¥7.17B | ¥7.40B | ¥5.08B |
Shares Outstanding | Not available | Not available | Not available | Not available |